A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer
Latest Information Update: 08 May 2024
At a glance
- Drugs Azacitidine (Primary) ; Entinostat (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 01 May 2024 Number of treatment arms increased from 4 to 6 by the addition of 2 more experimental arms- arm A and arm B.
- 10 Apr 2024 Results presented at the 115th Annual Meeting of the American Association for Cancer Research
- 06 Jun 2023 Status changed from active, no longer recruiting to completed.